Precision BioSciences, Inc.(DTIL)Earnings, Financials & Key RatiosPrecision BioSciences, Inc. (DTIL) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's reliance on lumpy milestone payments and the absence of recurring revenue, evidenced by a 2026Q1 net margin of -170.2%, suggest that the current business model lacks the stability required for long-term capital appreciation.
Precision BioSciences, Inc. (DTIL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Precision BioSciences, Inc. (DTIL) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.34vs $0.27-25.9% | $11Mvs $4M+167.6% |
| Q2 2026 | Mar 12, 2026 | $0.36vs $0.21+271.4% | $34Mvs $9M+276.9% |
| Q4 2025 | Nov 3, 2025 | $1.84vs $0.31-493.5% | $13,000vs $9M-99.9% |
| Q3 2025 | Aug 7, 2025 | $2.13vs $0.09-2266.7% | $18,000vs $5M-99.7% |
Recent stock market news and headlines for Precision BioSciences, Inc. (DTIL)
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUSÂ platform to develop in vivo gene edit
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced its addition to the Russell 2000® Index, effective at the close of U.S. equity markets on June 26, 2026, according to the final list of additions published by FTSE Russell. The annual reconstitution of the Russell U.S. indexes ranks eligible U.S. sto.
Key metrics vs top competitors for Precision BioSciences, Inc. (DTIL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $9.25 | $118.66M | -2.55 | -50.12% | -136.03% | -62.71% | — | |
| $37.92 | $3.9B | -46.81 | 120.01% | -49.17% | -5.89% | — | |
| $60.77 | $5.86B | -9.39 | -89.97% | -13856.54% | -30.88% | — | |
| $3.75 | $367.15M | -2.08 | 25.39% | -281.59% | -677.39% | — | |
| $17.43 | $1.96B | -4.57 | 16.92% | -597.04% | -57.27% | — | |
| $3.02 | $352.01M | -2.63 | -51.24% | -2056.79% | -58.89% | — |
Precision BioSciences, Inc. (DTIL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Precision BioSciences, Inc. (DTIL) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 5, 2026·SEC
Mar 17, 2026·SEC
Mar 12, 2026·SEC
Get notified when DTIL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Precision BioSciences, Inc. (DTIL) stock FAQ — growth, dividends, profitability & financials explained
Precision BioSciences, Inc. (DTIL) reported $45.1M in revenue for fiscal year 2025. This represents a 543% increase from $7.0M in 2016.
Precision BioSciences, Inc. (DTIL) saw revenue decline by 50.1% over the past year.
Precision BioSciences, Inc. (DTIL) reported a net loss of $44.5M for fiscal year 2025.
Precision BioSciences, Inc. (DTIL) has a return on equity (ROE) of -62.7%. Negative ROE indicates the company is unprofitable.
Precision BioSciences, Inc. (DTIL) had negative free cash flow of $58.8M in fiscal year 2025, likely due to heavy capital investments.
